Back to today’s briefing

Story perspectives

Tempus AI's $200M Deal Boosts Shares, Revolutionizes Cancer Discovery

4/24/2025

36 5

Summary

Story summary

Tempus AI has forged a groundbreaking $200 million partnership with AstraZeneca and Pathos AI to create a cutting-edge multimodal foundation model for oncology. This innovative collaboration seeks to revolutionize cancer drug discovery by leveraging Tempus' vast de-identified data. The news sent Tempus shares soaring by 17%, showcasing investors' enthusiasm for its AI-driven vision for better patient outcomes.

1 of 1

Story summary

Tempus AI has forged a groundbreaking $200 million partnership with AstraZeneca and Pathos AI to create a cutting-edge multimodal foundation model for oncology. This innovative collaboration seeks to revolutionize cancer drug discovery by leveraging Tempus' vast de-identified data. The news sent Tempus shares soaring by 17%, showcasing investors' enthusiasm for its AI-driven vision for better patient outcomes.